Topic: coronary artery disease
The primary endpoint successes in patients with stable CAD or AMI set Idorsia up to plan the initiation of a phase 3 study.
XyloCor Therapeutics will move its lead asset, a gene therapy for chronic angina, into the clinic in 2019.
The FDA approved Biotronik’s stent to seal tears in coronary arteries, making it the first new treatment option in the indication in 17 years.
A discontinued heart disease drug will be developed for sickle cell, with Roche handing off its inclacumab antibody to Global Blood Therapeutics.
A tool called “polygenic risk scoring” could help physicians identify who faces a high risk of serious diseases.
Reva netted a CE mark for the first drug-eluting bioresorbable scaffold in lower-leg peripheral artery disease, and the company’s first in the space.
Biotech developments over the past week include a new idea for halting metastasis in breast cancer and a new method for reversing atherosclerosis.
The round equips HeartFlow to accelerate commercialization of its algorithmic, noninvasive test of coronary disease while rolling out new studies.
Hospitals enrolled in Medicare will soon receive reimbursement for HeartFlow's noninvasive technology for coronary artery disease analysis.